Literature DB >> 30571175

Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy.

Alessandro Mantovani1, Stefano Bonapace2, Gianluigi Lunardi3, Matteo Salgarello4, Clementina Dugo2, Stefania Gori3, Enrico Barbieri2, Giuseppe Verlato5, Reijo Laaksonen6,7, Christopher D Byrne8,9, Giovanni Targher1.   

Abstract

Objective- It is known that specific plasma ceramides are associated with stress-induced reversible myocardial perfusion defects in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy (MPS). However, it is currently uncertain whether plasma ceramides are also associated with reduced poststress myocardial perfusion in these patients. Approach and Results- We measured 6 previously identified high-risk plasma ceramide species (ceramide [d18:1/16:0], ceramide [d18:1/18:0], ceramide [d18:1/20:0], ceramide [d18:1/22:0], ceramide [d18:1/24:0], and ceramide [d18:1/24:1]) in 167 consecutive patients with established or suspected coronary artery disease undergoing stress MPS for clinical indications. Plasma ceramides were measured by a targeted liquid chromatography-tandem mass spectrometry assay both at baseline and after MPS. Multivariable linear regression analysis was undertaken to examine the associations (standardized B coefficients) between plasma ceramides and the percentage of poststress myocardial perfusion after adjustment for multiple cardiovascular risk factors. Seventy-eight patients had stress-induced myocardial ischemia on MPS (mainly located in the anteroapical wall). Of the 6 measured plasma ceramides, higher levels of basal ceramide (d18:1/18:0; B=-0.182; P=0.019), ceramide (d18:1/20:0; B=-0.224; P=0.004), ceramide (d18:1/22:0; B=-0.163; P=0.035), and ceramide (d18:1/24:1; B=-0.20; P=0.010) were associated with lower poststress anteroapical wall perfusion. Notably, these significant associations persisted even after adjustment for conventional cardiovascular risk factors, previous coronary artery disease, electrocardiographic left bundle branch block, left ventricular ejection fraction and type of stress testing. Similar results were observed for poststress plasma ceramides. Conclusions- Higher circulating levels of specific ceramides, both at baseline and after stress, were independently associated with lower poststress anteroapical wall perfusion in patients with suspected or established coronary artery disease referred for clinically indicated MPS.

Entities:  

Keywords:  ceramides; coronary artery disease; patients; perfusion; risk factors

Mesh:

Substances:

Year:  2018        PMID: 30571175     DOI: 10.1161/ATVBAHA.118.311927

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease.

Authors:  Annelise M Poss; J Alan Maschek; James E Cox; Benedikt J Hauner; Paul N Hopkins; Steven C Hunt; William L Holland; Scott A Summers; Mary C Playdon
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 2.  Cholesterol - the devil you know; ceramide - the devil you don't.

Authors:  Trevor S Tippetts; William L Holland; Scott A Summers
Journal:  Trends Pharmacol Sci       Date:  2021-11-05       Impact factor: 14.819

3.  You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.

Authors:  Joseph V Varre; William L Holland; Scott A Summers
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-23       Impact factor: 5.228

4.  DES1: A Key Driver of Lipotoxicity in Metabolic Disease.

Authors:  Jeremy T Blitzer; Liping Wang; Scott A Summers
Journal:  DNA Cell Biol       Date:  2020-03-16       Impact factor: 3.311

Review 5.  Ceramides and other sphingolipids as drivers of cardiovascular disease.

Authors:  Ran Hee Choi; Sean M Tatum; J David Symons; Scott A Summers; William L Holland
Journal:  Nat Rev Cardiol       Date:  2021-03-26       Impact factor: 49.421

6.  Association between ceramides and coronary artery stenosis in patients with coronary artery disease.

Authors:  Chenchen Tu; Lan Xie; Zhenjie Wang; Lili Zhang; Hongmei Wu; Wei Ni; Caixia Li; Lin Li; Yong Zeng
Journal:  Lipids Health Dis       Date:  2020-06-25       Impact factor: 3.876

Review 7.  Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease.

Authors:  Bhagirath Chaurasia; Chad Lamar Talbot; Scott A Summers
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

8.  Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial.

Authors:  Giovanni Targher; Gianluigi Lunardi; Alessandro Mantovani; Jennifer Meessen; Stefano Bonapace; Pier Luigi Temporelli; Enrico Nicolis; Deborah Novelli; Antonio Conti; Luigi Tavazzi; Aldo Pietro Maggioni; Roberto Latini
Journal:  ESC Heart Fail       Date:  2020-07-06

Review 9.  Ceramides in Metabolism: Key Lipotoxic Players.

Authors:  Bhagirath Chaurasia; Scott A Summers
Journal:  Annu Rev Physiol       Date:  2020-11-06       Impact factor: 19.318

Review 10.  Metabolic Messengers: ceramides.

Authors:  Scott A Summers; Bhagirath Chaurasia; William L Holland
Journal:  Nat Metab       Date:  2019-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.